EA200400427A1 - Применение человеческого хорионического гонадотропина и лютеинизирующего гормона при контролируемой гиперстимуляции яичников - Google Patents

Применение человеческого хорионического гонадотропина и лютеинизирующего гормона при контролируемой гиперстимуляции яичников

Info

Publication number
EA200400427A1
EA200400427A1 EA200400427A EA200400427A EA200400427A1 EA 200400427 A1 EA200400427 A1 EA 200400427A1 EA 200400427 A EA200400427 A EA 200400427A EA 200400427 A EA200400427 A EA 200400427A EA 200400427 A1 EA200400427 A1 EA 200400427A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lutinesising
horionic
gonadotropin
human
application
Prior art date
Application number
EA200400427A
Other languages
English (en)
Other versions
EA009330B1 (ru
Inventor
Ив Менезо
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Резеч Системз Арс Холдинг Н.В. filed Critical Апплайд Резеч Системз Арс Холдинг Н.В.
Publication of EA200400427A1 publication Critical patent/EA200400427A1/ru
Publication of EA009330B1 publication Critical patent/EA009330B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение предоставляет последовательность операций, ведущую к увеличению частоты имплантации эмбриона и/или снижению частоты выкидышей, причем чХГ или его биологический аналог вводят в течение фолликулярной фазы.Отчет о международном поиске был опубликован 2003.12.18.
EA200400427A 2001-09-12 2002-09-12 Способ содействия имплантации и/или снижения частоты выкидышей и набор для его осуществления EA009330B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01307757 2001-09-12
PCT/GB2002/004158 WO2003022302A2 (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION

Publications (2)

Publication Number Publication Date
EA200400427A1 true EA200400427A1 (ru) 2004-08-26
EA009330B1 EA009330B1 (ru) 2007-12-28

Family

ID=8182261

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400427A EA009330B1 (ru) 2001-09-12 2002-09-12 Способ содействия имплантации и/или снижения частоты выкидышей и набор для его осуществления

Country Status (20)

Country Link
US (1) US7405197B2 (ru)
EP (1) EP1425032A2 (ru)
JP (1) JP2005501918A (ru)
KR (1) KR20040032954A (ru)
CN (1) CN100536912C (ru)
AR (1) AR036592A1 (ru)
BR (1) BR0212429A (ru)
CA (1) CA2457849A1 (ru)
EA (1) EA009330B1 (ru)
HK (1) HK1067867A1 (ru)
HR (1) HRP20040087A2 (ru)
IL (1) IL160780A0 (ru)
ME (1) MEP39208A (ru)
MX (1) MXPA04002256A (ru)
NO (1) NO20040991L (ru)
PL (1) PL369098A1 (ru)
RS (1) RS21004A (ru)
UA (1) UA82650C2 (ru)
WO (1) WO2003022302A2 (ru)
ZA (1) ZA200400835B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258568A1 (en) * 2003-02-07 2006-11-16 Austia Wirtschaftsservice Gesellschaft Mit Beschrankter Use of human chorionic gonadotropin in the treatment in the treatment of symptoms endometriosis
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20150273020A1 (en) * 2007-05-11 2015-10-01 Lori R. Bernstein Hormone Normalization Therapy and Uses Therefor
EP2243423B1 (de) * 2009-04-23 2012-05-02 Roche Diagnostics GmbH Verfahren und Gerät zur Ermittlung von Empfehlungen für Wirkstoffdosierungen anhand von Messserien zumindest eines physiologischen Parameters eines Patienten
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
KR20140053991A (ko) * 2011-07-18 2014-05-08 아츠 바이올로직스 에이/에스 장기간 작용하는 황체 형성 호르몬 (ｌｈ) 화합물
US10271876B2 (en) 2011-11-23 2019-04-30 Mezadata Medical Ip Holding Llc Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
MX2015004940A (es) 2012-10-18 2015-12-09 Neuralight Hd Llc Tratamiento de depresion y ptsd.
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
MX2019000498A (es) 2016-07-21 2019-09-16 ObsEva SA Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos.
CA3035055A1 (en) 2016-08-29 2018-03-08 Progena, Inc. Autologous somatic stem cell therapy, method of controllable preparation of therapeutic composition and procedure of adaptive treatment of ivf patient
RU2646578C1 (ru) * 2017-02-13 2018-03-05 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия им. С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Способ повышения эффективности имплантации эмбриона в естественном цикле зачатия и в протоколах вспомогательных репродуктивных технологий
CN109431647B (zh) * 2018-09-20 2020-10-30 华中农业大学 一种杂交水牛同期发情-定时输精的处理方法
WO2021043726A1 (en) 2019-09-03 2021-03-11 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4103750A1 (en) 2020-02-10 2022-12-21 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
EP0994718B1 (en) 1997-06-20 2005-08-17 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
ZA987497B (en) * 1997-09-08 1999-02-23 Akzo Nobel Nv Expression of gonadotropins in dictyostelium
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
BR0008468A (pt) * 1999-02-24 2002-02-05 Novo Nordisk As Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos
ATE332705T1 (de) * 1999-05-07 2006-08-15 Applied Research Systems Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
BR0107881A (pt) * 2000-01-27 2003-04-01 Applied Research Systems Uso de fsh tratamento de infertilidade

Also Published As

Publication number Publication date
AR036592A1 (es) 2004-09-22
JP2005501918A (ja) 2005-01-20
BR0212429A (pt) 2004-10-26
CN1553808A (zh) 2004-12-08
PL369098A1 (en) 2005-04-18
HRP20040087A2 (en) 2004-12-31
HK1067867A1 (en) 2005-04-22
UA82650C2 (ru) 2008-05-12
MXPA04002256A (es) 2004-07-23
US7405197B2 (en) 2008-07-29
EA009330B1 (ru) 2007-12-28
MEP39208A (en) 2011-02-10
CA2457849A1 (en) 2003-03-20
ZA200400835B (en) 2005-04-26
NO20040991L (no) 2004-03-08
RS21004A (en) 2006-12-15
KR20040032954A (ko) 2004-04-17
US20050065069A1 (en) 2005-03-24
CN100536912C (zh) 2009-09-09
WO2003022302A2 (en) 2003-03-20
WO2003022302A3 (en) 2003-12-18
IL160780A0 (en) 2004-08-31
EP1425032A2 (en) 2004-06-09

Similar Documents

Publication Publication Date Title
EA200400427A1 (ru) Применение человеческого хорионического гонадотропина и лютеинизирующего гормона при контролируемой гиперстимуляции яичников
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
BR9713294A (pt) "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano"
ATE83374T1 (de) Neue galenische form von fenofibrat.
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
CY1111291T1 (el) Υγρα ή αποξηραμενα με παγο φαρμακευτικα σκευασματα fsh και/ή lh μαζι με τον mh-iontiko επιφανειοδραστικο παραγοντα poloxamer 188 και εναν βακτηριοστατικο παραγοντα
EA200000310A1 (ru) April - новый белок, воздействующий на рост
PT944396E (pt) Composicoes e processos para melhorar o funcionamento gastrointestinal
IL159177A0 (en) Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
ES2162917T3 (es) Mejoras en o relativas al suministro de peptidos.
CY1110991T1 (el) Χρηση των hcg και lh στην ελεγχομενη διεγερση των ωοθηκων
CY1110487T1 (el) Χρηση της lh σε ελεγχομενη υπερδιεγερση των ωοθηκων
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
WO2002097044A3 (en) Alternative splice forms of proteins as basis for multiple therapeutic modalities
DE60335726D1 (de) Chromoprotein und fluoroproteine
IL145689A0 (en) Methods
ES2042461T1 (es) Producto y procedimiento para el te\ido oxidativo del cabello.
BR0211951A (pt) Farinha de glúten de proteìna branca e métodos de uso
ECSP034743A (es) Peptidos a partir del anticuerpo 16/61d para tratar lupus eritematoso sistemico
ATE397081T1 (de) Erhöhte expression von proteinen mittels gfp
ATE355302T1 (de) N-substituierte d-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
ATE500790T1 (de) Knochennagel zum versorgen von frakturen
NO971508L (no) Analoger av sur fibroblastvekstfaktor med forökt stabilitet og biologisk aktivitet
ES2185652T3 (es) Oligopeptidos derivados de fragmentos de proteinas c-reactiva.

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU